Back

EAU 2023 - The 38th Annual European Association of Urology Congress 2023

Mar 10 - Mar 13, 2023 | MilanItaly

LARVOL is not affiliated with The 38th Annual European Association of Urology Congress 2023 and all trademarks, logos, and brand names are property of their respective owners

Top Trials

Showing 79 abstracts linked to Trials

A0108 - How should lesions without anatomical correspondence in 18F-PSMA-1007 PET/CT be interpreted - a PROSTAGE follow-up study

  • On-demand

A0009 - Orgasmic function worsening could lead to erectile function decrease after holep – Results from a prospective trial (expho)

  • On-demand

A0015 - Holmium Laser Enucleation of the Prostate is associated with complications and sequelae even in the hands of an experienced surgeon. Results from a prospective series

  • On-demand

V093 - Finals results in the safety and performance evaluation of a drop-in gamma probe for sentinel lymph node dissection in prostate cancer

V098 - Salvage radical prostatectomy following 177Lu-PSMA-617 radioligand therapy in men with high-risk localized prostate cancer: surgical aspects of the LuTectomy study

A0955 - 68Ga-PSMA-PET/CT in patients starting on Active Surveillance for PRostate cancer - Trial (PASPoRT)

A0960 - MRI-guided Active Surveillance without annual re-biopsy in patients with ISUP 1 and 2 prostate cancer – The prospective PROMM-AS Study

A0964 - Four-year follow-up of MRI-guided transurethral ultrasound ablation (TULSA) in men with localized prostate cancer

  • On-demand

A0965 - Salvage transurethral ultrasound ablation (TULSA) for localized radio-recurrent prostate cancer: 12-month safety and oncological outcomes

  • On-demand

A0966 - 12-month clinical outcomes of MRI-guided transurethral ultrasound ablation for localized prostate cancer

  • On-demand

A0968 - Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: experience from the first study on clinical efficacy

  • On-demand

A0969 - Transperineal targeted microwave ablation for low to intermediate-risk prostate cancer: results of a phase I-II study (NCT04627896)

  • On-demand